Literature DB >> 15649820

Betulinic acid derivatives as HIV-1 antivirals.

Christopher Aiken1, Chin Ho Chen.   

Abstract

Betulinic acid (BA) derivatives are low molecular weight organic compounds synthesized from a plant-derived natural product. Several BA derivatives are potent and highly selective inhibitors of HIV-1. Depending on the specific side-chain modification, these compounds function by inhibiting HIV fusion or, as recently demonstrated, by interfering with a specific step in HIV-1 maturation. BA derivatives have potential as novel HIV-1 therapies, and additional studies of their mechanisms of action are likely to further define the novel targets of these compounds and elucidate the basic biology of HIV-1 fusion and maturation. In this review, recent studies of the novel mechanisms of action of this interesting class of antiviral compounds are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15649820     DOI: 10.1016/j.molmed.2004.11.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  46 in total

1.  Domain-swapped dimerization of the HIV-1 capsid C-terminal domain.

Authors:  Dmitri Ivanov; Oleg V Tsodikov; Jeremy Kasanov; Tom Ellenberger; Gerhard Wagner; Tucker Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

Review 2.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

3.  3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro.

Authors:  Michael Sakalian; Curtis P McMurtrey; Frederick J Deeg; Christopher W Maloy; Feng Li; Carl T Wild; Karl Salzwedel
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Ionic derivatives of betulinic acid as novel HIV-1 protease inhibitors.

Authors:  Hua Zhao; Shaletha S Holmes; Gary A Baker; Suresh Challa; Himangshu S Bose; Zhiyan Song
Journal:  J Enzyme Inhib Med Chem       Date:  2011-10-10       Impact factor: 5.051

Review 5.  Natural compounds as anticancer agents: Experimental evidence.

Authors:  Jiao Wang; Yang-Fu Jiang
Journal:  World J Exp Med       Date:  2012-06-20

Review 6.  HIV-1 Capsid Inhibitors as Antiretroviral Agents.

Authors:  Suzie Thenin-Houssier; Susana T Valente
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

7.  Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein.

Authors:  Brian N Kelly; Sampson Kyere; Isaac Kinde; Chun Tang; Bruce R Howard; Howard Robinson; Wesley I Sundquist; Michael F Summers; Christopher P Hill
Journal:  J Mol Biol       Date:  2007-08-15       Impact factor: 5.469

8.  Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.

Authors:  Catherine S Adamson; Michael Sakalian; Karl Salzwedel; Eric O Freed
Journal:  Retrovirology       Date:  2010-04-20       Impact factor: 4.602

9.  Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).

Authors:  Catherine S Adamson; Kayoko Waki; Sherimay D Ablan; Karl Salzwedel; Eric O Freed
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

10.  The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain.

Authors:  Sandrina Dafonseca; Pascale Coric; Bernard Gay; Saw See Hong; Serge Bouaziz; Pierre Boulanger
Journal:  Virol J       Date:  2008-12-23       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.